sequences (Hannon 2002). These gene-silencing techusing the MBP Ac1-11-specific V␣2.3/V␤8.2 transgenic splenocytes in which the vast majority of T cells recogniques offer several advantages over gene knockout and monoclonal antibody technologies for studying nize the peptide. The splenocytes were transfected with the AS oligos or siRNAs that had been bound to a transin vitro and in vivo roles of specific genes. First, mice that have a specific gene deleted may have altered the fection agent to maximize transfection into the cells. Transfected splenocytes were activated with MBP Ac1-normal requirements for that protein during development, and the observed phenotypes may not be the 11, and nuclear extracts were prepared. Western blot analysis with anti-T-bet demonstrated that T-bet protein same in a normal animal that has a gene suppressed in vitro or in vivo. Second, the gene is deleted from all expression was induced upon activation with MBP Ac1-11 and that this induction was inhibited in the activated cell types, which may make it difficult to determine the relevance of that gene in particular cell types that may splenocytes that were transfected with the siRNA and AS oligo specific for T-bet ( Figures 1A and 1C) . Densiplay a role in the disease or pathway of interest. Third, monoclonal antibodies do not inhibit the expression of tometry of the T-bet and ␤-actin blots was performed, and the relative protein expression of T-bet was deterthe protein, but they do interfere with the function of the protein, and their use is typically limited to membrane mined by normalizing the density of the T-bet bands to the ␤-actin bands ( Figures 1B and 1D ). The level of bound and secreted proteins, not intracellular proteins such as transcription factors. In the present study, we T-bet expression in mock-transfected TCR V␤8.2 varies slightly between mice in the absence of antigen, as seen demonstrate that an AS oligo and siRNA specific for T-bet can be utilized to target T-bet both in vitro and in Figure 1 . Interestingly, when T-bet expression is detectable in the mock-transfected cells without antigen in vivo to define the role of T-bet in the differentiation of autoreactive T cells and as a potential therapeutic activation, as seen in Figures 1C and 1D , AS-Tbet can suppress the level of endogenous T-bet in the cells even target for Th1-mediated diseases.
in the absence of antigen. To evaluate the efficiency of the transfection of the Results AS oligos and siRNAs into the primary splenocyte cultures, the AS oligos and siRNAs were labeled with fluoGeneration of T-bet-Specific Antisense Oligonucleotides and Small Interfering RNA rescein prior to splenocyte transfection. The cell suspensions were evaluated by fluorescent microscopy To determine if suppression of T-bet may be beneficial in altering the development of encephalitogenic T cells, after transfection. The number of total cells versus the number of fluorescein-labeled cells showed that we conwe developed an AS oligo and siRNA specific for T-bet (Table 1) . Two control AS oligos were also generated, sistently transfected Ͼ90% of the nonadherent splenocytes (Figure 2 ). one specific for GATA3, which would have minimal effect or may enhance encephalitogenicity of T cells, and one
To verify that the inhibition of T-bet resulted in the suppression of IFN␥ production, V␤8.2 transgenic splencontaining a nonsense sequence (Finotto et al., 2001 ). The AS oligos were generated on a phosphorothioate ocytes were transfected with the T-bet-specific AS oligo and siRNA and activated with MBP Ac1-11, supernatants backbone to increase their stability and minimize degradation. The siRNA specific for T-bet contains a 19 base were collected, and IFN␥ production was measured by ELISA. As seen in Figure 3A , IFN␥ production was supsequence within the open reading frame generated with AA overhangs at the 5Ј ends. The nonsense siRNA was pressed, but not totally inhibited, in the splenocytes that were transfected with the T-bet-specific nucleic acids, a random sequence that had no significant sequence similarity to other genes.
verifying that silencing T-bet significantly diminished IFN␥ production. IFN␥ production increases over time We investigated whether these T-bet-specific nucleic acids were capable of suppressing T-bet expression in in the cells in which T-bet was silenced, but it is not known whether this IFN␥ is expressed by CD4ϩ T cells MBP Ac1-11-specific T cells. Splenocytes were isolated from B10.PL mice that were transgenic for the V␤8.2 or other immune cells in the splenocyte population. There was no IL-4 produced when T-bet was silenced T cell receptor chain that recognizes MBP Ac1-11 when paired with a specific V␣2.3 T cell receptor chain (Goverduring the primary activation (data not shown). man et al., 1993). Naive V␤8.2 transgenic mice have a precursory frequency of MBP Ac1-11-specific T cells of Silencing T-bet Alters the Encephalitogenicity of MBP-Specific T Cells 1 in 10 3 -10 4 splenoctyes, this measure is more physiologically relevant in terms of the number of T cells in a To determine if suppressing T-bet could alter the encephalitogenic capacity of MBP Ac1-11-specific T cells, population specific for a particular antigen compared to Similarly, we examined LNC and splenocytes at day 13 postimmunization/siRNA or AS oligo treatment. None of the mice had developed clinical signs of EAE. At this time point, one would anticipate that the activated antigen-specific T cells would have migrated into the spleen. The level of T-bet in the splenocytes from the mice that received AS-Tbet or siRNA-Tbet was reduced by 60% and 98%, respectively, compared to the T-bet levels in the mice that received the AS-NS or siRNA-NS ( Figure 4F ). Antigen-specific IFN␥ production and proliferation were also examined. As seen in Figure 4G , both the splenocytes and LNC from the AS-NS-treated mice produced significant amounts of IFN␥ in response to the antigen. In contrast, there was no antigen-induced IFN␥ production in the splenocytes of the AS-Tbet-or siRNA-Tbet-treated mice, and only a modest amount of IFN␥ produced in LNC at 48 hr compared to the amount produced in LNC from the AS-NS-treated mice. LNC from the siRNA-Tbet-treated mice were not evaluated in this experiment because there were not enough cells recovered from the lymph nodes in these mice. However, in similar experiments not shown, there was no significant production of IL-4, IL-5, IL-10, or IFN␥ in LNC or splenocytes in the mice that received siRNA-Tbet or AS-Tbet. At day 13, LNC from all of the groups showed were not seen in thigh muscle at 5 days postinjection (data not shown). To further explore this observation, naive V␣2.3/V␤8.2 T-bet-specific immunoprecipitated DNA, but the STAT1 promoter could not be amplified from the T-bet-specific transgenic splenocytes were transfected with AS-Tbet and siRNA-Tbet prior to activation with Ac1-11 in the immunoprecipitated DNA from the cells that had been transfected with siRNA-Tbet ( Figure 6E ). This confirms presence of IL-12. Supernatants were collected from the cultured cells, and IFN␥ levels were determined by that T-bet directly binds the STAT1 promoter and regulates STAT1 expression in activated splenocytes. ELISA, demonstrating significant IFN␥ production in all transfection conditions ( Figure 5C ). At 72 hr postactivaTo determine if STAT1 may also regulate T-bet transcription in some type of feedback loop to optimize IFN␥ tion, the splenocytes were transferred into B10.PL mice, and all cells activated in the presence of IL-12 could production, a ChIP assay using anti-STAT1 to precipitate DNA/STAT1 complexes from activated V␤8.2 splentransfer disease into recipients, regardless of whether T-bet was silenced prior to activation ( Figure 5D ). These ocytes was performed. The 5Ј end of the T-bet gene could not be amplified in these experiments (data not data indicate that T-bet functions independently of IL-12 and/or upstream of IL-12 in the differentiation of the shown). However, due to the lack of data on the promoter/enhancer region of the T-bet gene, the primer encephalitogenic T cells.
The Role of T-bet in the Differentiation
sets that were used may not have been optimal. Therefore, we developed an siRNA specific for STAT1 and T-bet Regulates the IFN␥ and STAT1 Genes investigated whether reducing STAT1 expression alTo determine what genes T-bet may directly regulate in tered T-bet expression. Naive V␤8.2 splenocytes were the Th1 differentiation pathway, chromatin immunopretransfected with siRNA-STAT1 and activated with MBP cipitation (ChIP) assays were utilized. Naive V␤8.2 transAc1-11. Nuclear extracts were prepared and analyzed genic splenocytes were activated in vitro with MBP Ac1-for STAT1, T-bet, and ␤-actin protein levels. As seen 11 and then fixed with formaldehyde to crosslink T-bet/ in Figure 6F , STAT1 expression in activated cells was DNA complexes. The cells were sonicated, and anti-Treduced by 47% by the siRNA, which is significant given bet was used to immunoprecipitate the DNA specifically that STAT1 is constitutively expressed by a variety of bound to T-bet. The immunoprecipitated DNA was puricell types in the spleen. In addition, T-bet expression fied, and PCR amplification was used to identify prowas reduced by 50% when the splenocytes were transmoter/enhancer regions of various genes that had been fected with siRNA-STAT1, confirming the previously bound to T-bet. As seen in Figure 6A , the IFN␥ could be published observation that STAT1 regulates T-bet examplified with the IFN␥ promoter primer set #7, verifying pression (Afkarian, et al.
, 2002). that the IFN␥ gene may be directly regulated by T-bet
Since it had been reported that IL-12R␤2 mRNA was in these autoreactive T cells. Similarly, we immunoprenot upregulated in T-bet-deficient mice, suggesting that cipitated DNA bound to STAT1 from antigen-activated T-bet regulated the IL-12R␤2 gene (Afkarian et al., 2002), V␤8.2 cells and amplified the IFN␥ gene with two primer we investigated whether we could confirm this observasets ( Figure 6B ). We also used STAT1 and STAT4 protion in our experimental system. First, we performed moter/enhancer region-specific primers to determine if ChIP assays on activated V␤8.2 cells with anti-T-bet and these genes may be regulated by T-bet. As expected, attempted to PCR amplify the promoter region of the the STAT4 gene was not amplified from the DNA precipi-IL-12R␤2 gene, but we were not successful (data not tated with the T-bet antibody (data not shown). However, shown). Given that a negative result in this experiment a primer set specific for the STAT1 promoter region does not preclude the possibility of T-bet regulating amplified a segment from T-bet-immunoprecipitated this gene, we analyzed IL-12R␤2 protein expression in DNA ( Figure 6C verifying that STAT1 and T-bet levels were significantly that has a pathogenic effect in vivo by using two genesilencing techniques. We utilized MBP Ac1-11-specific suppressed when the T-bet gene was silenced. 
TCR transgenic T cells that preferentially differentiate

MBP Ac1-11-specific T cells is 1 in 10
3
-10 4 splenocytes, tion capacity. In contrast to T-bet-deficient mice, no increase in Th2 cytokines was seen in mice that received which is a more physiologically relevant number than the number of splenocytes from V␣2.3/V␤8.2 TCR transa single dose of AS-Tbet or siRNA-Tbet. The role of T-bet in experimental models of inflammagenic mice in which Ͼ90% of the splenic T cells respond to MBP Ac1-11. In addition, exogenous cytokines and tory diseases has been studied previously in model systems. T-bet deficiency was found to protect from Th1-antibodies to cytokines that are often added to T cell cultures to drive the differentiation of the cells were not mediated experimental colitis in an adoptive transfer model, and T-bet-deficient mice were found to be more used in most of these studies; thus, we could access the extent of T-bet's role in Th1 differentiation when the susceptible to an actively induced Th2-mediated colitis (Neurath et al. 
, 2002). This finding suggests that T-bet source of cytokines was limited to the antigen-presenting cells and responding T cells. T-bet expression in plays a critical role in these T cell-mediated inflammatory diseases. Similarly, Con-A-induced liver injury was ovalbumin-specific T cell receptor transgenic cells differentiated in vitro demonstrated varied levels of T-bet ameliorated in T-bet-deficient mice (Siebler et al., 2003). However, T-bet-deficient Balb/c mice immunized with expression under different Th1-inducing conditions (Afkarian et al., 2002). Since the primary source of IFN␥ an insulin peptide develop diabetes-related phenotypes similar to wild-type Balb/c mice, indicating that T-bet and IL-12 during the differentiation of Th1 cells in vivo is the antigen-presenting cells, NK cells, and CD8ϩ does not play a critical role in this inflammatory model (Melanitou et al., 2003). It has been shown recently that T cells, we thought that stimulation of splenocytes with antigen alone provided the most accurate assessment T-bet-deficient mice are resistant to actively induced EAE and develop a Th2 phenotype (Bettelli et al. 2004). of T-bet's role in the differentiation of naive cells since all of these cell populations are present in primary splenIn contrast to these previous studies, we studied the role of T-bet in T-bet-competent mice by using geneocyte cultures. T-bet expression was induced upon activation of naive V␤8.2 TCR splenocytes with MBP Ac1-silencing techniques. Suppression of T-bet during the in vitro differentiation of myelin-reactive T cells dimin-11, as originally observed in T cell clones activated with PMA/ionomycin or anti-CD3 (Szabo et al., 2000). Both ished the capacity of these cells to cause EAE when transferred into naive mice. More importantly, in vivo the AS oligo and siRNA specific for T-bet could effectively suppress T-bet protein expression in MBP Ac1-administration of the siRNA or AS oligo specific for T-bet prevented the onset of actively induced EAE, suggesting 11-stimulated V␤8.2 TCR transgenic splenocytes. IFN␥ levels were substantially reduced in the splenocyte culthat T-bet may be a viable target for therapeutic intervention in Th1-mediated diseases. tures that had been transfected with the T-bet-specific
10
Ϫ5 M 2-ME, and nonessential amino acids. The cells were transcells from wild-type B10.PL mice. The protein concentration was determined by using the BioRad Protein Assay. Immulon II plates fected with AS oligos and siRNAs as described below. Splenocytes from wild-type B10.PL mice were irradiated with 3000 rads and were coated with 20 g/ml protein in 0.1 M NaHCO 3 (pH 8.2) overnight at 4ЊC. The plates were washed twice with PBS/Tween and cultured in 24-well plates at 6 ϫ 10 6 cells per well in RPMI 1640 supplemented as described above, except the fetal bovine serum blocked with PBS/BSA for 2 hr, and anti-IL-12R␤2, anti-STAT1, and anti-T-bet were added at 5 g/ml into duplicate wells for 2 hr. The concentration was increased to 10% and pencillin/streptomycin were added at 100 U/ml. MBP Ac1-11 peptide was added to the plates were washed six times with PBS/Tween, and a biotinylated secondary antibody was added at 2 g/ml for 1 hr. The remainder cultures at 2 g/ml. Table 1 .
For in vitro transfection of splenocytes, 2 l TransIT-TKO transfec-4%-20%) SDS-PAGE gels and were transferred to nitrocellulose membranes. The membranes were blocked with 5% milk in TBS. tion reagent (Mirus) was diluted in 50 l serum-free/antibiotic-free RPMI 1640 media per well. After a 10 min incubation at room temperThe primary antibody was usually diluted 1:100 in blocking buffer and was added to the membrane for 2 hr. The membrane was ature, 1 l 40 M siRNA or 2 l 20 M AS oligo was added to 52 l diluted transfection reagent. The AS oligos and siRNAs were washed three times in TBS/Tween. The secondary antibody bound to HRP was diluted 1:1000 and was added to the membrane for 1 incubated with the diluted transfection reagent at room temperature with gentle agitation for 30 min. The AS oligos or siRNAs were added hr. The membrane was washed three times, and a chemiluminescent substrate (Santa Cruz Biotechnology, Inc.) was added for 1 min; the to the V␤8.2 transgenic splenocyte cultures containing 5 ϫ 10 6 cells in 500 l media per well of a 24-well plate and incubated overnight blot was then exposed to film for various times (0.05-10 min). T-bet antibody, STAT1 antibody, IL-12R␤2 antibody, goat anti-mouse IgGat 37ЊC. On the following day, the nonadherent cells were collected and washed with fresh media. The adherent cells in the plates were HRP, and anti-goat IgG-HRP were purchased from Santa Cruz Biotechnology, Inc. The density of the bands was determined by using also washed once with fresh media. The nonadherent cells were resuspended in 2 ml media and placed back in their original wells.
an AlphaImager (Alpha Innotech Corp.). The data was normalized by dividing the density of the T-bet or STAT1 band by the density MBP Ac1-11 peptide was added at 2 g/ml. For V␣2.3/V␤8.2 transgenic splenocytes, 2 ϫ 10 6 splenocytes were placed in each well of the ␤-actin band. of a 24-well plate. The transfection protocol was the same, except the cells were placed with wild-type splenocytes (6 ϫ 10 6 cells/well) Chromatin Immunoprecipitation Assays that had been irradiated and cultured with MBP Ac1-11 after the 24
We used a modified version of the technique previously described hr transfection.
( protein complexes was collected after centrifugation to remove the cell debris. An aliquot of the supernatant was set aside for a positive well for 2 hr. The plates were then washed twice with PBS/Tween, and 100 l supernatants was added in duplicate. The plates were control in the PCR reactions, because all the DNA from the cells is contained in the supernatant. An antibody known to immunoprecipiincubated overnight at 4ЊC and washed four times with PBS/Tween. Biotinylated rat anti-mouse IFN␥ (Pharmingen) was diluted in PBS/ tate the transcription factor of interest, as well as an isotype control antibody, was added to the supernatant to bind the DNA/transcrip-1% BSA, 100 l of 1 g/ml biotinylated antibody was added to each well, and plates were incubated at room temperature for 1 hr. The tion factor complexes. All of the antibodies were the same as those used in the Western blot. After a 24 hr incubation at 4ЊC, protein A plates were washed six times with PBS/Tween, and 100 l avidinperoxidase was added at 2.5 g/ml and incubated for 30 min. The sepharose beads were added and incubated at room temperature for 2 hr. The beads were washed, and the immune-complexes were plates were washed eight times with PBS/Tween, and 100 l ABTS substrate containing 0.03% H 2 O 2 was added to each well. The plate eluted from the beads with SDS/NaHCO 3 . The formaldehyde crosslinks from the immunoprecipitated DNA/protein complexes, as well was monitored for 15-20 min for color development and read at OD 405 . A standard curve was generated from the IFN␥ standards, as the total DNA/protein complexes, were reversed by adding 3 M NaOAc to a final concentration of 0.3 M and incubating at 65ЊC and the concentration of IFN␥ in the samples was calculated.
For IL-12R␤2, STAT1, and T-bet, whole-cell lysates were generovernight. The DNA was precipitated with EtOH at -20ЊC. The remaining protein was degraded by Proteinase K digestion at 42ЊC ated from 2 ϫ 10 6 V␣2.3/V␤8.2 TCR transgenic splenocytes that have been activated with MBP Ac1-11 plus 6 ϫ 10 6 irradiated feeder for 2 hr. The DNA was purified by phenol:chloroform extraction, 
